LAG3 and breast carcinoma: Nowadays, inhibitors of LAG-3 are investigating in clinical trials to treat other types of malignancies like breast cancer; evidences appeared to be promising due to survival rate of 50%, which might provide consistent rationale to apply this strategy for mesothelioma treatment as well (131).